Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 2 clients • 11 examiners • 7 art units • 0 of 11 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Clark+Elbing LLP - Genentech and Roche operates in the Biotechnology & Pharmaceuticals technology area, with 12 pending office actions currently on the docket. This activity is situated within the firm's total career history of 8984 applications. The 12 pending office actions indicate the current level of engagement for these specific clients. The firm's extensive work in Biotechnology & Pharmaceuticals is reflected in their 8984 career applications.
The resolved allowance rate for the firm is 67.87 percent, a figure derived from their 8984 career applications. This 67.87 percent rate provides a measure of success for applications reaching a final disposition. Prosecution at the firm averages 3.89 office actions per allowance. This 3.89 average is a metric for practitioners estimating the timeline for patent grants. With 12 pending office actions, the firm continues its work in the life sciences sector. The 67.87 percent allowance rate and 3.89 office action average define the firm's prosecution profile in Biotechnology & Pharmaceuticals.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (18%) |
| §112 only | 4 (36%) |
| Double-patenting + other | 3 (27%) |
| Multi-statute (no §101) | 2 (18%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HALVORSON, MARK | 1 | 47.9% | +20.7% |
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
| KIM, YUNSOO | 1 | 65.9% | +34.3% |
| SITTON, JEHANNE SOUAYA | 1 | 53.2% | +48.0% |
| CUNNINGCHEN, KATHLEEN MARY | 1 | 61.1% | +62.5% |
| NOAKES, SUZANNE MARIE | 1 | 73.3% | +18.2% |
| DEBERRY, REGINA M | 1 | 50.1% | +30.6% |
| SAOUD, CHRISTINE J | 1 | 58.0% | +37.2% |
| ALLEN, MARIANNE P | 1 | 60.1% | +18.2% |
| HOWARD, ZACHARY C | 1 | 64.0% | +37.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18799503 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR BLADDER CANCER | GUSTILO, ESTELLA M | — |
| 18174889 | METHODS FOR PRODUCING ANTIBODIES | HOWARD, ZACHARY C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18329972 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR IL-33-MEDIATED DISORDERS | SITTON, JEHANNE SOUAYA | 52d overdue |
| 18295539 | DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES | ALLEN, MARIANNE P | 26d overdue |
| 18933358 | BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS | HALVORSON, MARK | — |
| 18799503 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR BLADDER CANCER | GUSTILO, ESTELLA M | — |
| 18600194 | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE | KIM, YUNSOO | — |
| 18324406 | METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS | CUNNINGCHEN, KATHLEEN MARY | — |
| 18309003 | RECOMBINANT PROTEINS FOR QUANTIFICATION OF PROTEIN LEVELS | NOAKES, SUZANNE MARIE | — |
| 18301180 | HYALURONIC ACID BINDING DERIVATIVES OF VERSICAN (VG1) FOR LONG ACTING DELIVERY OF THERAPEUTICS | DEBERRY, REGINA M | — |
| Client (Assignee) | Pending OAs |
|---|---|
| GENENTECH, INC. | 8 |
| Roche | 3 |
| Art Unit | Apps |
|---|---|
| 1646 | 3 |
| 1647 | 2 |
| 1682 | 1 |
| 1656 | 1 |
| 1645 | 1 |
| 1674 | 1 |
| 1643 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18933358 | BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS | Genentech, Inc. | HALVORSON, MARK | 1646 | §103Other | Non-Final OA | — | Pending | Oct 31, 2024 |
| 18799503 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR BLADDER CANCER | Genentech, Inc. | GUSTILO, ESTELLA M | 1646 | §102§103§112Other | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18600194 | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE | Genentech, Inc. | KIM, YUNSOO | §103DP | Non-Final OA | — | Pending | Mar 08, 2024 | |
| 18329972 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR IL-33-MEDIATED DISORDERS | Genentech, Inc. | SITTON, JEHANNE SOUAYA | 1682 | §103 | Final Rejection | 52d overdue | Pending | Jun 06, 2023 |
| 18324406 | METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS | Genentech, Inc. | CUNNINGCHEN, KATHLEEN MARY | 1646 | §112 | Non-Final OA | — | Pending | May 26, 2023 |
| 18309003 | RECOMBINANT PROTEINS FOR QUANTIFICATION OF PROTEIN LEVELS | Genentech, Inc. | NOAKES, SUZANNE MARIE | 1656 | §112 | Non-Final OA | — | Pending | Apr 28, 2023 |
| 18301180 | HYALURONIC ACID BINDING DERIVATIVES OF VERSICAN (VG1) FOR LONG ACTING DELIVERY OF THERAPEUTICS | Hoffmann-La Roche, Inc. | DEBERRY, REGINA M | 1647 | §102§103§112DP | Non-Final OA | — | Pending | Apr 14, 2023 |
| 18301187 | NON-COVALENT PROTEIN-HYALURONAN CONJUGATES FOR LONG-ACTING OCULAR DELIVERY | Hoffmann-La Roche, Inc. | SAOUD, CHRISTINE J | 1645 | §102§103§112DP | Non-Final OA | — | Pending | Apr 14, 2023 |
| 18295539 | DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES | Genentech, Inc. | ALLEN, MARIANNE P | 1647 | §112 | Final Rejection | 26d overdue | Pending | Apr 04, 2023 |
| 18174889 | METHODS FOR PRODUCING ANTIBODIES | Genentech, Inc. | HOWARD, ZACHARY C | 1674 | §103§112 | Non-Final OA | — | Pending | Feb 27, 2023 |
| 18066529 | PROTEASE-ACTIVATED T CELL BISPECIFIC ANTIBODIES | Hoffmann-La Roche, Inc. | CHATTIN, AMY MARIE | 1643 | §112Other | Non-Final OA | 26d | Pending | Dec 15, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial